BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karwaciak I, Sałkowska A, Karaś K, Dastych J, Ratajewski M. Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism. Int J Mol Sci 2021;22:5034. [PMID: 34068624 DOI: 10.3390/ijms22095034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Pastwińska J, Karaś K, Karwaciak I, Ratajewski M. Targeting EGFR in melanoma - The sea of possibilities to overcome drug resistance. Biochim Biophys Acta Rev Cancer 2022;1877:188754. [PMID: 35772580 DOI: 10.1016/j.bbcan.2022.188754] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Wang Z, Liu Y, Zhang J, Zhao R, Zhou X, Wang H. An Immune-Related Long Noncoding RNA Signature as a Prognostic Biomarker for Human Endometrial Cancer. J Oncol 2021;2021:9972454. [PMID: 34925511 DOI: 10.1155/2021/9972454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
3 Ge L, Wu Y, Wan M, You Y, Zhai Z, Song Z. Metformin Increases Sensitivity of Melanoma Cells to Cisplatin by Blocking Exosomal-Mediated miR-34a Secretion. J Oncol 2021;2021:5525231. [PMID: 34880915 DOI: 10.1155/2021/5525231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gracia-Hernandez M, Munoz Z, Villagra A. Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers. Cancers (Basel) 2021;13:6180. [PMID: 34944799 DOI: 10.3390/cancers13246180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mitra A, Ghosh R. A375 melanoma cells are sensitized to cisplatin-induced toxicity by a synthetic nitro-flavone derivative 2-(4-Nitrophenyl)-4H-chromen-4-one through inhibition of PARP1. Mol Biol Rep 2021. [PMID: 34342816 DOI: 10.1007/s11033-021-06600-w] [Reference Citation Analysis]